Callahan Margaret K
From the Melanoma and Immunotherapy Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center; and Weill Medical College, Cornell University, New York, NY.
Cancer J. 2016 Mar-Apr;22(2):73-80. doi: 10.1097/PPO.0000000000000183.
Checkpoint-blocking antibodies have transformed cancer therapy, and the treatment of patients with metastatic melanoma has led the revolution. Herein, we review the current clinical data supporting the use of checkpoint-blocking antibodies in the treatment of melanoma and highlight outstanding clinical questions and unmet clinical needs.
检查点阻断抗体已经改变了癌症治疗方式,转移性黑色素瘤患者的治疗引领了这场革命。在此,我们回顾目前支持使用检查点阻断抗体治疗黑色素瘤的临床数据,并强调突出的临床问题和未满足的临床需求。